Literature DB >> 27257135

Bladder Preservation Therapy: A Review of the Literature and Future Directions.

David B Cahn1, Benjamin T Ristau2, Eric M Ghiraldi3, Thomas M Churilla4, Daniel M Geynisman5, Eric M Horwitz4, Robert G Uzzo6, Marc C Smaldone2.   

Abstract

Trimodal bladder preservation therapy (ie, transurethral resection followed by chemoradiotherapy) may be an acceptable treatment alternative to radical cystectomy with urinary diversion in the carefully selected patient with muscle invasive bladder cancer. Although no head-to-head randomized controlled trials have been performed, large retrospective cohort reviews and observational data analyses suggest comparable oncologic outcomes in select patients with the additional benefit of maximizing quality of life and maintaining the patient's native bladder. In this review, we discuss the evolution and clinical outcomes of bladder preservation therapy, highlighting its role in the contemporary management of muscle invasive bladder cancer.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27257135     DOI: 10.1016/j.urology.2016.05.041

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Conservative Management of Muscle Invasive Bladder Cancer in Kidney-Pancreas Transplant Patient.

Authors:  Logan D Glosser; Brandon S Zakeri; Conner V Lombardi; Obi O Ekwenna
Journal:  Case Rep Transplant       Date:  2022-05-29

2.  Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer.

Authors:  Tracy L Rose; Allison M Deal; Sylvain Ladoire; Gilles Créhange; Matthew D Galsky; Jonathan E Rosenberg; Joaquim Bellmunt; Akhila Wimalasingham; Yu-Ning Wong; Lauren C Harshman; Simon Chowdhury; Guenter Niegisch; Michalis Liontos; Evan Y Yu; Sumanta K Pal; Ronald C Chen; Andrew Z Wang; Matthew E Nielsen; Angela B Smith; Matthew I Milowsky
Journal:  Bladder Cancer       Date:  2016-10-27

3.  Low Grade Lymphoma Mimicking Metastatic Urothelial Carcinoma: When Do We Need Further Histologic Staging?

Authors:  Azka Ali; William P Skelton; Neeka N Akhavan; Thu-Cuc Nguyen; Zachary A Taylor; Tabitha Townsend; Prajwol Pathak; Nalini Hasija; Li Li; Jacqueline Indrisek; Scott Watson; Isis Nixon; Nam H Dang; Robert Zlotecki; Paul Crispen; Robert Allan; Patricia Abbitt; Long H Dang
Journal:  Case Rep Oncol Med       Date:  2016-11-22

4.  Synergy of Tumor Microenvironment Remodeling and Autophagy Inhibition to Sensitize Radiation for Bladder Cancer Treatment.

Authors:  Tingsheng Lin; Qing Zhang; Ahu Yuan; Baojun Wang; Feifei Zhang; Yuanzhen Ding; Wenmin Cao; Wei Chen; Hongqian Guo
Journal:  Theranostics       Date:  2020-06-19       Impact factor: 11.556

5.  Long-Term Experience of Chemoradiotherapy Combined with Deep Regional Hyperthermia for Organ Preservation in High-Risk Bladder Cancer (Ta, Tis, T1, T2).

Authors:  Ricarda Merten; Oliver Ott; Marlen Haderlein; Simone Bertz; Arndt Hartmann; Bernd Wullich; Bastian Keck; Reinhard Kühn; Claus Michael Rödel; Christian Weiss; Christine Gall; Wolfgang Uter; Rainer Fietkau
Journal:  Oncologist       Date:  2019-07-10

6.  Young age increases the risk of lymph-node metastasis in patients with muscle-invasive bladder urothelial carcinoma.

Authors:  Zijian Tian; Lingfeng Meng; Xin Wang; Tongxiang Diao; Maolin Hu; Miao Wang; Ming Liu; Jianye Wang
Journal:  BMC Cancer       Date:  2020-09-04       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.